Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease
Pemafibrate slows experimental AS progression and valve calcification through modulation of macrophage-VIC crosstalk, independent of lipid lowering. These findings support further evaluation of pemafibrate as a potential pharmacological approach for CAVD and support further testing in randomized clinical trials.
Authors
- Katelyn A. Perez (ORCID: https://orcid.org/0000-0003-3685-8212)
- Yusuke Sasaki (ORCID: https://orcid.org/0000-0001-7379-8066)
- Sasha Singh
- Takehito Okui
- Yuto Nakamura (ORCID: https://orcid.org/0000-0001-9608-9553)
- Mark C. Blaser (ORCID: https://orcid.org/0000-0002-3923-9786)
- Aruna D. Pradhan (ORCID: https://orcid.org/0000-0003-4321-5960)
- Luisa Weiß (ORCID: https://orcid.org/0000-0002-7018-5325)
- Adrien Lupieri (ORCID: https://orcid.org/0000-0002-9245-0169)
- Shinsuke Itoh (ORCID: https://orcid.org/0000-0001-9567-8188)
- Rei Itagawa
- Takeshi Tanaka (ORCID: https://orcid.org/0000-0003-0768-9528)
- Masanori Aikawa
- Elena Aikawa
- Taku Kasai
- Rile Ge
- Peter Libby
- Paul M Ridker
- Mandy E Turner
Institutions
- Brigham and Women's Hospital (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2025-12-19
- DOI
- https://doi.org/10.64898/2025.12.17.694919
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00